These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16264926)

  • 1. Re-induction of hormonal sensitivity in hormone-refractory prostate cancer--fact or fiction?
    Berry WR
    Nat Clin Pract Oncol; 2005 Apr; 2(4):180-1. PubMed ID: 16264926
    [No Abstract]   [Full Text] [Related]  

  • 2. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

  • 3. Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy.
    Cox RA; Sundar S
    Br J Cancer; 2008 Jan; 98(1):238-9. PubMed ID: 18182981
    [No Abstract]   [Full Text] [Related]  

  • 4. Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding.
    Shamash J; Dancey G; Barlow C; Wilson P; Ansell W; Oliver RT
    Br J Cancer; 2005 Jan; 92(1):36-40. PubMed ID: 15570307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent chemotherapy for metastatic hormone refractory prostate cancer.
    Lin AM; Ryan CJ; Small EJ
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):243-54. PubMed ID: 17161610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls.
    Syed S
    Cancer; 2003 Nov; 98(10):2088-90. PubMed ID: 14601076
    [No Abstract]   [Full Text] [Related]  

  • 7. Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
    Stadler WM; Michaelis LC; Ratain MJ
    J Clin Oncol; 2005 Nov; 23(31):8124-5; author reply 8125-6. PubMed ID: 16258115
    [No Abstract]   [Full Text] [Related]  

  • 8. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of hormonal refractory metastatic prostate cancer].
    Sengeløv L; Klarskov OP; Karlsson S
    Ugeskr Laeger; 2007 May; 169(20):1905-7. PubMed ID: 17553368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: hormone therapies for prostate cancer--acute disease control, chronic disease progression.
    Lamb DJ; Buttyan R
    J Urol; 2003 Apr; 169(4):1558. PubMed ID: 12629414
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chemotherapy of advanced prostate cancer].
    Murphy GP
    Vopr Onkol; 1977; 23(12):26-38. PubMed ID: 146305
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemotherapy for the treatment of hormone-refractory prostate cancer.
    Chowdhury S; Burbridge S; Harper PG
    Int J Clin Pract; 2007 Dec; 61(12):2064-70. PubMed ID: 17956560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain metastases in hormone refractory prostate cancer: a changing natural history?
    Roberts-Thomson R; Rosenthal MA; Gonzales M; Drummond K
    Intern Med J; 2009 Mar; 39(3):205-6. PubMed ID: 19383072
    [No Abstract]   [Full Text] [Related]  

  • 14. A long and winding road: the role of chemotherapy for hormone-refractory prostate cancer.
    Higgins GS; Stewart GD; McNeill SA; McLaren DB
    Int J Clin Pract; 2007 Dec; 61(12):1964-5. PubMed ID: 17997800
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of systemic cytotoxic therapy for prostate cancer.
    Chang SS; Kibel AS
    BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The benefits of early androgen blockade.
    Maroni PD; Crawford ED
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of hormone refractory prostate cancer.
    Lin AM; Small EJ
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):187-91. PubMed ID: 18685361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy for hormone-refractory prostate cancer].
    Tsushima T
    Nihon Rinsho; 1998 Aug; 56(8):2167-72. PubMed ID: 9750528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial.
    Lin CC; Hsu CH; Hour TC; Cheng AL; Huang CY; Huang KH; Chen J; Pu YS
    Urol Oncol; 2007; 25(3):207-13. PubMed ID: 17483017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies in development for castrate-resistant prostate cancer.
    Harzstark AL; Ryan CJ
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):259-68. PubMed ID: 18279066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.